Quantcast

Latest Named patient programs Stories

2009-03-30 16:30:00

INSMED WILL CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL IPLEX(TM) INITIATIVES IN THE U.S. IDIS WILL HAVE RESPONSIBILITY FOR REST OF WORLD RICHMOND, Va., March 30 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced the signing of an agreement with IDIS, a private, UK-based company specializing in the management of medicines on a named patient basis, also known as expanded access programs (EAPs) or named patient programs (NPPs), to manage...

2008-09-18 09:00:49

LONDON, Sept. 18 /PRNewswire/ -- IDIS, the world leader in the development and implementation of Named Patient Programs (NPPs), will sponsor the first-of-its-kind conference on pre-launch access to drugs in Baltimore, MD, on October 22-23. This conference will bring together industry experts to present and exchange information on programs that enable patients with unmet medical needs to get access to drugs in the pre-launch phase. Industry leaders will discuss the fundamentals of US-based...

2008-08-27 09:01:27

DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Pacific Healthcare Thailand Co., Ltd. (Pacific), a specialty pharmaceutical company based in Bangkok, under which Pacific will act as DOR's Sponsor to administer a...

2008-07-15 09:01:35

DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents, announced today that it has executed a definitive collaborative agreement with IDIS Limited ("IDIS"), for the supply and distribution within the European Union of the Company's investigational drug orBec(R) (oral beclomethasone...

2008-06-16 21:00:24

SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis today announced the appointment of IDIS Limited to manage and provide eligible patients worldwide with access to Bronchitol through a Named Patient Program. The program will allow patients who are unable to participate in current Pharmaxis clinical trials but who are considered by their physician to be suffering from a clinical condition for which no satisfactory authorised alternative exists, to receive access to...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related